Emicizumab does not interfere with the activated clotting time.

Ladislas CapdevilaCorinne FrèreMaximilien DesvagesAnnie HarrocheCécile BallyAhmed AbbesRoseline d'Oiron Laurent FrenzelDelphine BorgelDominique Lasne

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2022)

Emicizumab does not interfere with UFH-induced ACT prolongation. The hemochron® ACT can be used to monitor UFH in patients receiving emicizumab during CPB or cardiac catheterization.

Keyphrases

drug induced
high glucose
diabetic rats
left ventricular
ultrasound guided
heart failure
endothelial cells
atrial fibrillation